Drug intelligence / Profile preview

PD-FA

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems

Overview

PD-FA is a folic acid-decorated palladium decahedral nanoenzyme designed to enhance the efficacy of iodine-125 (125I) seed radiotherapy, particularly in hypoxic tumor environments. It functions by targeting tumor regions and catalyzing the conversion of intracellular hydrogen peroxide (H2O2) into oxygen (O2), thereby alleviating tumor hypoxia. Additionally, the palladium component enhances the deposition of radiotherapeutic energy within tumor tissues, leading to improved radiosensitization. Its prolonged in vivo circulation, compared to palladium nanodots, allows for sustained radiosensitization.

Other names: folic acid-decorated palladium decahedral platformdecahedral nanoenzyme

Beyond the preview

Go deeper on PD-FA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-FA.

Explore the full profile